Aim To review the clinical course, outcome and incidence of infantile salt wasting associated with urinary tract infection (UTI) and/or urinary tract malformation (UTM) over a two‐year surveillance period on the island of Ireland. Methods A two‐year (2013‐14) prospective surveillance undertaken via the Irish and Ulster Paediatric Surveillance Units. Monthly prepaid postcards were circulated to consultant paediatricians (n = 260) at all paediatric units on the island of Ireland. Infants under one year of age presenting for the first time with hyponatraemia (Na < 130 mmol/L) and/or hyperkalaemia (K > 5.0 mmol/L) associated with urosepsis/UTM were reported. Results All 7 reported patients (6 male) had culture‐proven UTI, and 5 (71%) also had an underlying UTM (one diagnosed antenatally). Four (57%) patients had a documented elevated serum aldosterone supporting secondary pseudohypoaldosteronism (PHA) as the underlying diagnosis. Data on aldosterone were not reported in the other 3 patients, but clinical features were suggestive of secondary PHA. The estimated incidence for the Irish population of transient PHA is 1 per 13,200 total live births per year. Conclusions Salt wasting is a rare complication of UTI, especially if associated with underlying UTM. Boys appear to be at particular risk.

Barring few clinical circumstances which put these young infants at increased risk of clinically important traumatic brain injury, a vast majority of minor head injury in infants can be safely observed at home with reliable caretakers and proper discharge instructions.

No abstract

No abstract

with F2F resuming after this date. Patients were excluded if they had been diagnosed since March 2020 or had transferred to our hospital. Results 78 patients pre covid and 83 patients during covid were included in analysis.Duration between HbA1c blood tests pre covid showed a mean of 3.1 months with a range of 1-7months. During covid the mean duration between tests was 10.9 months with a range of 7-18 months. See figure 1 Change in HbA1c in each patient was measured from baseline. Baseline was considered to be the first measurement from March 2019 in the 'pre covid group' and the last pre covid measurement in the 'during covid group'.The majority of patients (78%) in the year pre covid and 65% during covid stayed within -10 and +10 mmol/ml of their baseline. However, during covid there were more large increases in HbA1c. This demonstrated in figure 2.A comparison was also made with the national targets for HbA1c. The most striking difference is the number of patients with HbA1c >80mmol/ml. Increasing from 9 pre covid (11.5%) to 28 during covid (34%). There were also fewer patients reaching the target of <48mmol/ml halving from 14 to 7 (18% to 8%).